Cohort | Disease | Regimens | Primary outcome measure |
---|---|---|---|
Cohort 1 | Unresectable AJCC stage 3 or 4 melanoma | Anti-PD-1 monotherapy (nivolumab or pembrolizumab) | 1 year PFS |
Cohort 2 | Unresectable AJCC stage 3 or 4 melanoma | Ipilimumab+nivolumab | 1 year PFS |
Cohort 3 | Advanced renal cell carcinoma | Anti-PD-(L)1 + kinase inhibitor | 1 year PFS |
Cohort 4 | Advanced renal cell carcinoma | Ipilimumab+nivolumab | 1 year PFS |
Cohort 5 | Advanced NSCLC | Anti-PD-(L)1 monotherapy in the first-line setting | 1 year PFS |
Cohort 6 | Advanced NSCLC | Anti-PD-(L)1 + chemotherapy ± antiangiogenic in the first-line setting | 1 year PFS |